Highlights

• June-quarter cash balance of approximately A$1m with relatively low operating cash burn reported

• YCDI (You Can Do It!) platform integration advancing alongside the core TALi attention-therapy product

• Management assessing AI-related opportunities to enhance the digital education and healthcare technology platform

• Recent announcements centred on securities issuance and preparations for Shareholder approval processes

TALi Digital Limited (ASX:TD1) is an ASX-listed digital health and education technology company that has built its reputation around the TALi Train attention-therapy program — a clinically validated digital intervention for children aged 3–8 with attention difficulties, developed from research at the Murdoch Children's Research Institute. The company has been broadening its platform beyond the initial ADHD-related attention focus through the integration of the YCDI (You Can Do It!) school wellbeing program, and is now exploring AI-enabled opportunities to extend both the clinical and educational dimensions of its offering.

Latest Developments

TALI Digital continues to progress its digital-learning and healthcare technology strategy, with recent announcements centred on securities issuance and preparations for shareholder approval. The company has reported a June-quarter cash balance of approximately $1 million and relatively low operating cash burn. Management is also assessing AI-related opportunities, while continuing integration of its YCDI platform and development of digital education tools.

Understanding the Business

TALi Digital's core offering is the TALi Train cognitive Training platform, designed for children with attention deficits who may or may not have a formal ADHD diagnosis. The platform uses digital games to train sustained attention across multiple sessions, with clinical research supporting its efficacy. The YCDI (You Can Do It!) program, integrated through an earlier acquisition, broadens the platform toward whole-of-school social-emotional learning — covering resilience, confidence, organisation and persistence across the primary school age range. Together, the two programs position TALi Digital as a school and clinical platform for children's cognitive and social-emotional development.

Industry Opportunity

Children's digital health and school wellbeing programs represent an increasingly well-funded category, with Australia's state education systems and the NDIS both providing funding pathways for clinically validated digital therapeutics and school wellbeing programs. The global digital therapeutics market — software-based clinical interventions that are prescribed or recommended by clinicians — is at an early but rapidly growing stage, and products with strong clinical evidence like TALi Train are positioned to benefit from the growing acceptance of digital health tools in paediatric care settings. The AI enhancement opportunity could expand both the personalisation and scalability of TALi's platform.

Key Risks

• Cash balance of approximately A$1m is very tight — ongoing securities issuance signals the need for ongoing external funding

• The TALi and YCDI platform integration needs to demonstrate combined commercial value that is greater than either standalone product

• School and clinical adoption cycles are long — TALi's products require school curriculum approval processes or clinical prescription pathways

• AI exploration does not yet represent a defined product or commercial strategy — it adds optionality but not near-term revenue

• Competition from larger digital health and education technology companies with greater Marketing resources

Key Catalysts to Watch

• YCDI integration delivering the first evidence of combined platform commercial wins across both school and clinical settings

• AI-enhanced product launch demonstrating personalised attention training or wellbeing support capabilities

• New government or school system contract providing recurring Revenue from a public-sector buyer

• NDIS funding pathway for TALi Train or YCDI enabling individual funding claims that support consumer adoption

• International expansion — particularly the UK or North American school and clinical markets — opening new revenue geographies

Conclusion

TALi Digital (ASX:TD1) has built something genuinely distinctive: a clinically researched attention-therapy platform for children that is now being expanded with school wellbeing and AI capabilities. The challenge is funding and commercialising this vision at a pace that matches the tight cash position. The YCDI integration and AI exploration are strategically sound directions, but they need to produce commercial results faster than the current trajectory suggests. Investors should monitor the YCDI integration progress and any new school or clinical contract announcements as the key near-term indicators.